HR Execs on the Move

Hitech Air Conditioning Inc

www.hitechair.net

 
Hitech Air Conditioning Inc is a Santee, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.hitechair.net
  • 10107 Prospect Ave Ste B
    Santee, CA USA 92071
  • Phone: 619.440.2080

Executives

Name Title Contact Details

Similar Companies

CoreLab Partners

CoreLab Partners is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gaia Herbs

Gaia Herbs has established itself as the leading grower and producer of Certified Organic (COG) herbs and herbal products. Gaia Herbs strives to produce pure plant medicines of exceptional quality and purity while enriching the ecology of the earth and the health and harmony of the people that use our phyto-medicines. Gaia Herbs is a certified organic grower and nationally-branded manufacturer of liquid herbal extracts based in Western NC. Find our products at health food retailers and co-ops, natural products retail chains, and healthcare professionals. Our commitment to certified organic herbs ensures strength, purity, and efficacy of our herbal products.

Banner Pharmacaps Inc

Banner is a global gelatin-based drug delivery and specialty pharmaceutical company. We are committed to researching, developing and producing unique oral dosage forms for the Pharmaceutical Health Care Industry. Through our innovative technologies and

SwitchGear Genomics (Main)

SwitchGear Genomics (Main) is a Menlo Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eupraxia Pharmaceuticals

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.